Very disappointing regarding no CE yet.
Personally I don't think management has pushed BSI strongly enough. BSI people probably spending more time reading about Brexit, and looking for new jobs than finishing their recommendation.
That said, DK has said imminent in strong words in last few presentations, so once all back to work, me thinks January has to be the month. Only a few good stories in the market right now and particularly in biotech land. Once formal notice is given (positive of course, given there-section data etc), this stock could really hit the after burners, as not much certainty to buy into.
Also 6 underbidders in SRX, a good investor experience there and OSL has different and first line technology which can go across the oncology market, not just pancreas and liver.
Hold on and buy more. Down here looking to wade into some more.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.020(2.00%) |
Mkt cap ! $14.50M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 99.5¢ | $44.55K | 44.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 192 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 6234 | 1 |
View Market Depth
| Last trade - 15.48pm 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |